Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Journal
The Lancet Oncology
ISSN
1470-2045
Date Issued
2019
Author(s)
Georgina V Long
Reinhard Dummer
Omid Hamid
Thomas F Gajewski
Christian Caglevic
Stephane Dalle
Ana Arance
Matteo S Carlino
Jean-Jacques Grob
Tae Min Kim
Lev Demidov
Caroline Robert
James Larkin
James R Anderson
Janet Maleski
Mark Jones
Scott J Diede
Tara C Mitchell
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85069822789
WoS ID
WOS:000477712400035
DOI
URL
URL Institutional Repository
Subjects
indoleamine 2

; 

3-dioxygenase

; 

poor-prognosis

; 

ipilimumab

; 

expression

; 

ido

; 

nivolumab

; 

immune

; 

adult

; 

aged

; 

antibodies, monoclonal, humanized

; 

antineoplastic combined chemotherapy protocols

; 

double-blind method

; 

female

; 

humans

; 

male

; 

melanoma

; 

middle aged

; 

oximes

; 

progression-free survival

; 

sulfonamides

; 

alanine aminotransferase

; 

amylase

; 

aspartate aminotransferase

; 

creatine kinase

; 

epacadostat

; 

gamma glutamyltransferase

; 

pembrolizumab

; 

placebo

; 

programmed death 1 ligand 1

; 

triacylglycerol lipase

; 

troponin

; 

antineoplastic agent

; 

epacadostat

; 

monoclonal antibody

; 

oxime

; 

pembrolizumab

; 

sulfonamide

; 

abdominal pain

; 

abnormally high substrate concentration in blood

; 

acute hepatitis

; 

acute kidney failure

; 

acute pancreatitis

; 

adrenal insufficiency

; 

adult

; 

aged

; 

alanine aminotransferase blood level

; 

amylase blood level

; 

anaphylaxis

; 

anemia

; 

anxiety disorder

; 

arthralgia

; 

arthritis

; 

article

; 

aspartate aminotransferase blood level

; 

asthenia

; 

atopic dermatitis

; 

autoimmune colitis

; 

autoimmune disease

; 

autoimmune hepatitis

; 

autoimmune nephritis

; 

autoimmune thyroiditis

; 

backache

; 

cancer growth

; 

cancer staging

; 

chronic inflammatory demyelinating polyradiculoneuropathy

; 

chronic obstructive lung disease

; 

colitis

; 

conjunctivitis

; 

controlled study

; 

creatine kinase blood level

; 

cytokine release syndrome

; 

deep vein thrombosis

; 

demyelinating disease

; 

diabetes mellitus

; 

diabetic ketoacidosis

; 

diarrhea

; 

double blind procedure

; 

drug dose reduction

; 

drug efficacy

; 

drug hypersensitivity

; 

drug safety

; 

drug tolerability

; 

dyspnea

; 

eosinophilia

; 

erythema multiforme

; 

erythroderma

; 

fatigue

; 

female

; 

follow up

; 

gamma glutamyl transferase blood level

; 

genital edema

; 

guillain barre syndrome

; 

hepatitis

; 

human

; 

hyperglycemia

; 

hyperlipasemia

; 

hypersensitivity

; 

hypertension

; 

hyperthyroidism

; 

hypoalbuminemia

; 

hyponatremia

; 

hypophosphatemia

; 

hypophysitis

; 

hypopituitarism

; 

hypothyroidism

; 

inflammation

; 

infusion related reaction

; 

insulin dependent diabetes mellitus

; 

intention to treat analysis

; 

interstitial lung disease

; 

leukocyte count

; 

liver function

; 

lung disease

; 

lung embolism

; 

lung sarcoidosis

; 

lymphocytopenia

; 

maculopapular rash

; 

major clinical study

; 

male

; 

metastatic melanoma

; 

monocyte count

; 

myocarditis

; 

myopathy

; 

myositis

; 

nausea

; 

neck pain

; 

nephritis

; 

neuralgia

; 

neutropenia

; 

neutrophil count

; 

open study

; 

overall survival

; 

pancreatitis

; 

phase 3 clinical trial

; 

side effect

; 

thrombocytopenia

; 

thyroid disease

; 

thyroiditis

; 

treatment response

; 

triacylglycerol lipase blood level

; 

tumor flare

; 

ulcerative colitis

; 

uveitis

; 

vitiligo

; 

vomiting

; 

clinical trial

; 

melanoma

; 

middle aged

; 

multicenter study